1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
    31.
    发明授权
    1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 失效
    用于治疗或预防包含1,2,4-噻二唑-3,5-二酮化合物的药物的药物组合物

    公开(公告)号:KR100837785B1

    公开(公告)日:2008-06-13

    申请号:KR1020070005148

    申请日:2007-01-17

    Abstract: A novel 1,2,4-thiadiazolidine-3,5-dione compound is provided to show excellent activity and enzyme selectivity on Lck SH2, thereby being usefully used for treating and preventing inflammation related diseases such as rheumatoid arthritis with high selectivity without side effects. A pharmaceutical composition for treating and preventing a disease induced by inflammation comprises a 1,2,4-thiadiazolidine-3,5-dione compound represented by a formula(1) or a pharmaceutically acceptable salt thereof as an effective ingredient. In the formula(1), A is linear or branched saturated or unsaturated C1-7 alkyl, indenyl, (C1-7)alkoxycarbonyl(C1-7)alkyl, phenyl, benzyl or C2H5(C=O)HR2R3(wherein A may be substituted by halogen, carboxyl, C1-7 alkoxycarbonyl, C1-7 alkoxy, nitro or hydroxy when A is alkyl, phenyl or benzyl); R1 is H, linear or branched saturated or unsaturated C1-7 alkyl, (C1-7)alkoxycarbonyl(C1-7)alkyl, phenyl, phenyl(C1-5)alkyl or phenylcarbonylmethyl; and each R2 and R2 is independently H, linear or branched saturated or unsaturated C1-7 alkyl or phenyl, or R2 and R3 may form a ring together with C1-5 alkylene. A pharmaceutical composition for treating and preventing rheumatoid arthritis comprises the 1,2,4-thiadiazolidine-3,5-dione compound of the formula(1) or a pharmaceutically acceptable salt thereof as an effective ingredient.

    Abstract translation: 提供了一种新的1,2,4-噻二唑烷-3,5-二酮化合物,以显示对Lck SH2的极好的活性和酶选择性,从而有效地用于治疗和预防炎症相关疾病如类风湿性关节炎,具有高选择性,无副作用 。 用于治疗和预防炎性疾病的药物组合物包含由式(1)表示的1,2,4-噻二唑烷-3,5-二酮化合物或其药学上可接受的盐作为有效成分。 在式(1)中,A是直链或支链饱和或不饱和的C1-7烷基,茚基,(C1-7)烷氧基羰基(C1-7)烷基,苯基,苄基或C2H5(C = O)HR2R3(其中A可以 苯基或苄基)被卤素,羧基,C 1-7烷氧基羰基,C 1-7烷氧基,硝基或羟基取代。 R1是H,直链或支链饱和或不饱和的C1-7烷基,(C1-7)烷氧基羰基(C1-7)烷基,苯基,苯基(C1-5)烷基或苯基羰基甲基; 并且每个R 2和R 2独立地为H,直链或支链饱和或不饱和的C 1-7烷基或苯基,或者R 2和R 3可与C 1-5亚烷基一起形成环。 用于治疗和预防类风湿性关节炎的药物组合物包含式(1)的1,2,4-噻二唑烷-3,5-二酮化合物或其药学上可接受的盐作为有效成分。

    3-메칠-(O-치환된 옥시이미노)-피라졸린-5-온 유도체를함유하는 항암제
    32.
    发明公开
    3-메칠-(O-치환된 옥시이미노)-피라졸린-5-온 유도체를함유하는 항암제 失效
    3-甲基 - (O-取代的氧代) - 吡唑啉-5-酮衍生物作为抗肿瘤剂

    公开(公告)号:KR1020050031716A

    公开(公告)日:2005-04-06

    申请号:KR1020030067964

    申请日:2003-09-30

    CPC classification number: A61K31/4152 A61K9/0053

    Abstract: An anticancer composition comprising 3-methyl-(O-substituted oximino)-pyrazolin-5-one derivatives is provided, which derivatives inhibit activity of CDC25B enzyme which participates in cell differentiation and is overexpressed in cancer cells. The anticancer composition comprises 3-methyl-(O-substituted oximino)-pyrazolin-5-one derivatives represented by formula (1), and pharmaceutically acceptable salts thereof, wherein R1 is C1-C4 alkyl or substituted phenyl with a substituent that is one or more selected from hydrogen, halogen atom, C1-C4 alkyl, C1-C4 alkoxy, C2-C4 acyl and nitro; and R2 is C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 acyl, methanesulfonyl, toluenesulfonyl, C1-C4 alkoxycarbonylmethyl, carboxymethyl or inorganic metal or organic amine salts of carboxymethyl.

    Abstract translation: 提供包含3-甲基 - (O-取代的肟基) - 吡唑啉-5-酮衍生物的抗癌组合物,该衍生物抑制参与细胞分化且在癌细胞中过表达的CDC25B酶的活性。 抗癌组合物包含由式(1)表示的3-甲基 - (O-取代的肟基) - 吡唑啉-5-酮衍生物及其药学上可接受的盐,其中R1是C1-C4烷基或具有取代基的取代苯基 或更多选自氢,卤素原子,C 1 -C 4烷基,C 1 -C 4烷氧基,C 2 -C 4酰基和硝基; R2为C1-C4烷基,C2-C4烯基,C2-C4炔基,C2-C4酰基,甲磺酰基,甲苯磺酰基,C1-C4烷氧基羰基甲基,羧甲基或羧甲基的无机金属或有机胺盐。

    믹소첼린-에이를 유효성분으로 하는 항산화 및 항암용약학 조성물
    33.
    发明授权
    믹소첼린-에이를 유효성분으로 하는 항산화 및 항암용약학 조성물 失效
    믹소첼린 - 에이를유효성분으로하는항산화및항암용약학조성물

    公开(公告)号:KR100424392B1

    公开(公告)日:2004-03-24

    申请号:KR1020010041239

    申请日:2001-07-10

    Abstract: PURPOSE: A pharmaceutical composition containing myxochelin-A which exhibits excellent anticancer activity against human cancer cells, together with excellent antioxidant activity as a main component is provided which can be effectively used as an effective antioxidant and anticancer agent. CONSTITUTION: The pharmaceutical composition contains myxochelin-A of formula 1 obtained by being separated from myxobacteria or being chemically synthesized or semisynthesized. The myxochelin-A is purely separated by the steps of: separating a biomass and absorption resin by culturing Angiococcus disciformis strains as myxobacteria in the presence of absorption resin and centrifuging a culture solution; adding an organic solvent, preferably a mixed solvent of acetone and methanol; extracting and filtering to remove the biomass and absorption resin; preparing an active fraction by concentrating the filtrate under reduced pressure and extracting a crude extract in an organic solvent; and successively performing silica gel liquid chromatography and recycling preparative HPLC.

    Abstract translation: 目的:提供一种药物组合物,其含有对人癌细胞具有优异的抗癌活性以及优异的抗氧化活性作为主要组分的粘液溶血素A,其可以有效地用作有效的抗氧化剂和抗癌剂。 组成:药物组合物含有通过从粘细菌分离或化学合成或半合成获得的式1的粘多糖蛋白-A。 通过在吸附树脂存在下离心培养溶液培养作为粘细菌的粘细菌属细菌菌株来分离生物质和吸附树脂,纯粹分离粘液粘连素-A; 加入有机溶剂,优选丙酮和甲醇的混合溶剂; 提取并过滤去除生物质和吸收树脂; 通过在减压下浓缩滤液并在有机溶剂中萃取粗提取物来制备活性部分; 并连续进行硅胶液相色谱和再循环制备型HPLC。

    4-O-[2-(N,N-디알킬아미노)-2-데옥시-4,6-O,O-(알케닐리덴 또는알키닐리덴)-β-D-글루코실]-4'-O-데메틸-에피-포도필로톡신 화합물, 이의 제조방법 및 이를 포함하는 항암제 조성물
    34.
    发明授权
    4-O-[2-(N,N-디알킬아미노)-2-데옥시-4,6-O,O-(알케닐리덴 또는알키닐리덴)-β-D-글루코실]-4'-O-데메틸-에피-포도필로톡신 화합물, 이의 제조방법 및 이를 포함하는 항암제 조성물 失效
    4-O- [2-(N,N-二烷基)-2-甲基-4,6-O,O-(알케닐덴덴덴또또알키닐덴덴)-β-D-글루실]] -4' - - 데메틸 - 에피 - 포도필로톡신화합물,이의제조방법및이를포함하는항암제조성물

    公开(公告)号:KR100418183B1

    公开(公告)日:2004-02-11

    申请号:KR1020000062778

    申请日:2000-10-25

    CPC classification number: Y02P20/55

    Abstract: PURPOSE: Provided is 4-O-(2-(N,N-dialkylamino)- 2-deoxy-4,6-O,O- (alkenylidene or alkynylidene)-beta-D- glucosyl)-4-O- dimethyl-epi-podophyllotoxin compound which is used in the treatment of cancers. Also, its producing method and an anticancer composition containing the same compounds are provided. CONSTITUTION: The 4-O-(2-(N,N-dialkylamino)- 2-deoxy-4,6-O,O- (alkenylidene or alkynylidene)-beta-D- glucosyl)-4-O- demethyl-epi-podophyllotoxin compound is represented by formula (1), in which R1 and R2 are individually hydrogen, C1 to C10 alkyl or C5 to C10 cycloalkyl or forms together C4 to C10 ring compounds having nitrogen atom; and R3 is linear or branched C1 to C8 alkyl, alkoxy, alkoxyalkyl or vinyl having aryl substituents, ethynyl, allyl, C3 to C10 cycloalkyl, C5 to C10 cycloalkenyl or C5 to C10 cycloalkynyl. The compound is produced by reacting a compound of formula (2) with aldehyde(3) or acetal of formula (4) in the presence of acid catalysts to produce a compound of formula (5); removing amino protecting group of formula (5) to produce compound of formula (6); and alkylation reacting the compound of formula (6) in the presence of reductase to produce the compounds of formula (1).

    Abstract translation: 用途:提供了4-O-(2-(N,N-二烷基氨基)-2-脱氧-4,6-O,O-(亚链烯基或亚炔基)-β-D-葡糖基)-4-O-二甲基 - 表鬼臼毒素化合物,用于治疗癌症。 此外,还提供了其制备方法和含有相同化合物的抗癌组合物。 组成:4-O-(2-(N,N-二烷基氨基)-2-脱氧-4,6-O,O-(亚链烯基或亚炔基)-β-D-葡糖基)-4-O-去甲基 - - 鬼臼毒素化合物由式(1)表示,其中R1和R2各自为氢,C1-C10烷基或C5-C10环烷基或一起形成具有氮原子的C4-C10环化合物; 并且R 3为直链或支链C 1至C 8烷基,烷氧基,烷氧基烷基或具有芳基取代基的乙烯基,乙炔基,烯丙基,C 3至C 10环烷基,C 5至C 10环烯基或C 5至C 10环炔基。 该化合物通过在酸催化剂存在下使式(2)化合物与醛(3)或式(4)缩醛反应生成式(5)化合物; 除去式(5)的氨基保护基以生成式(6)的化合物; (6)化合物在还原酶存在下进行烷基化反应,生成式(1)化合物。

    에피잔타틴의 아민 화합물 및 이의 제조방법
    35.
    发明授权
    에피잔타틴의 아민 화합물 및 이의 제조방법 失效
    表 - z他汀的胺化合物及其制备方法

    公开(公告)号:KR100180582B1

    公开(公告)日:1999-03-20

    申请号:KR1019950035587

    申请日:1995-10-16

    Abstract: 본 발명은 수용성이 우수하고 암세포의 성장 억제 효과를 나타내어 항암제로 사용 가능한 일반식(I)의 에피잔타틴의 아민 화합물, 이의 제조방법 및 이를 포함하는 항암제 조성물에 관한 것이다.

    상기식에서 X는 O, S, CR 또는 NR 이고; R은 수소 원자 또는 저급 알킬기이고; n은 0내지 2의 정수를 나타내며; 11번 탄소의 입체 화학은 R 또는 S이다.

    2, 3'-안히드로티미딘 화합물의 제조 방법
    36.
    发明公开
    2, 3'-안히드로티미딘 화합물의 제조 방법 无效
    2,3'-脱水胸苷化合物的制备方法

    公开(公告)号:KR1019970021089A

    公开(公告)日:1997-05-28

    申请号:KR1019950036500

    申请日:1995-10-20

    Abstract: 본 발명은 3′-치환-3′-데옥시티미딘, 특히 AZT의 제조에서 중간체로 사용되는 5′-히드록시 보호된 2,3′-안히드로티미딘의 제조 방법에 관한 것으로, 하기 일반식(1)의 5′-히드록시 보호-티미딘을 치환 또는 비치환 티오카르보닐디이미다졸과 반응시켜 하기 일반식(2)의 5′-히드록시 보호-3′-0-이미다졸릴티오카르보닐티미딘을 제조하고, 일반식(2)의 화합물을 염기 촉매 존재 또는 비존재하에 가열하는 단계를 포함하는 방법에 의하면, 3′-치환-3′-데옥시티미딘의 제조시 5′-히드록시 보호기가 산과 염기 조건하에서도 안정한 하기 일반식(3)의 5′-히드록시 보호된 2,3′-안히드로티미딘을 경제적으로 대량 합성할 수 있다.

    분자 소자용 π-공액성 화합물
    38.
    发明公开
    분자 소자용 π-공액성 화합물 失效
    π共轭化合物用于分子电子器件

    公开(公告)号:KR1020040003403A

    公开(公告)日:2004-01-13

    申请号:KR1020020038093

    申请日:2002-07-03

    Abstract: PURPOSE: A π-conjugate compound for molecular electronic devices is provided. The compound can be self-assembled, has easy electron-delocalized structure by π -conjugate linkage of total molecules, and properties to easily trap electron by electric filed produced from the outside because cation is contained within the molecules. CONSTITUTION: A π-conjugate compound for molecular electronic devices is characterized by being represented by the formula(1) of R¬1-Z- £Redox|¬1-Z-R¬2, containing center £Redox| capable of oxidation/reduction, and being connected to aromatic compounds directly or via acetylene bond,, wherein R1 is selected from benzene, CH3COS-benzene, CH3SS-benzene and SiS-benzene; R2 is selected from S-COCH3-benzene and (S-benzene)2; Z is single bond or triple bond; £Redox|1 is selected from X-N+R3-benzene, N+R3-naphthalene, and N+CH3CH3R3-naphthalene; R3 is selected from hydrogen, C1-C4 alkyl and benzyl; X- is selected from I-, Cl-, Br-, CF3SO3, CH3-benzene-SO3-, C12H25-benzene-SO3-, BF4-, PF6- and SbF6-.

    Abstract translation: 目的:提供分子电子器件的π-共轭化合物。 该化合物可以是自组装的,通过总共分子的π-共轭键具有容易的电子离域结构,以及由于阳离子包含在分子内而由外界产生的电场容易地捕获电子的性质。 构成:用于分子电子器件的π-共轭化合物的特征在于由式(1)表示:R 1-Z-£氧化还原|¬-Z-R-2,其含有中心£Redox | 能够进行氧化/还原,并直接或通过乙炔键与芳族化合物连接,其中R1选自苯,CH3COS-苯,CH3SS-苯和SiS-苯; R2选自S-COCH 3 - 苯和(S-苯)2; Z是单键或三键; £Redox | 1选自X-N + R3-苯,N + R3-萘和N + CH3CH3R3-萘; R3选自氢,C1-C4烷基和苄基; X-选自I-,Cl-,Br-,CF 3 SO 3,CH 3 - 苯-SSO 3 - ,C 12 H 25 - 苯-SSO 3 - ,BF 4 - ,PF 6 - 和SbF 6 - 。

Patent Agency Ranking